
Instil Bio (TIL) Stock Forecast & Price Target
Instil Bio (TIL) Analyst Ratings
Bulls say
Instil Bio Inc. has experienced a significant price surge, climbing nearly 500% following the release of the full HARMONi-2 dataset, indicating strong market enthusiasm and potential for positive catalysts, particularly with upcoming data from Summit Therapeutics' ivonescimab expected in mid-2025. The company's innovative CoStAR platform for genetically engineered tumor infiltrating lymphocyte therapies is positioned to potentially expand beyond its current indications, which, while not currently modeled, could enhance valuation and growth prospects. A discounted cash flow analysis estimates Instil Bio's firm value at approximately $884 million, suggesting a strong financial foundation bolstered by their cutting-edge approach to cancer treatment through checkpoint inhibition and anti-angiogenesis strategies.
Bears say
Instil Bio Inc reported a significant net loss of $1.82 per share for the fourth quarter of 2024, which is indicative of ongoing financial challenges. Projections for the full year 2025 anticipate an even greater net loss of $11.51 per share, reflecting worsened financial expectations compared to earlier estimates of $3.65 per share. Additionally, the company faces several operational risks, including potential delays in clinical trials and the possibility of unfavorable clinical data, which may further contribute to financial instability and shareholder dilution.
This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.
Instil Bio (TIL) Analyst Forecast & Price Prediction
Start investing in Instil Bio (TIL)
Order type
Buy in
Order amount
Est. shares
0 shares